PROM1 and hepatocellular carcinoma: In a phase I trial including 23 patients with several GI tumors treated with CD133-targeted CAR-T cells, 3 PR (2 pancreatic and 1 hepatocellular carcinoma [HCC]) and 14 SD were observed (39).